A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer

INTRODUCTION: Radium-223, abiraterone, and enzalutamide have each been shown to significantly improve survival as monotherapy in patients with metastatic castration-resistant prostate cancer. However, effects of combination radium-223 plus abiraterone or enzalutamide on survival and safety remain un...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:PLoS One
Autors principals: Kim, Stephanie I., Szeto, Andy H., Morgan, Katherine P., Brower, Blaine, Dunn, Mary W., Khandani, Amir H., Godley, Paul A., Rose, Tracy L., Basch, Ethan M., Milowsky, Matthew I., Whang, Young E., Crona, Daniel J.
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2021
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8216516/
https://ncbi.nlm.nih.gov/pubmed/34153052
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0253021
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars